A Phase I Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane (Paclitaxel Protein-Bound Particles) in Advanced Solid Cancers.

Trial Profile

A Phase I Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane (Paclitaxel Protein-Bound Particles) in Advanced Solid Cancers.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2014

At a glance

  • Drugs Paclitaxel (Primary) ; Sirolimus
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jan 2014 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
    • 16 Jun 2009 Planned end date changed from 1 Dec 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 05 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top